Evidence map›Paper›PMID 31273631›Full record

ArticleJournal of endocrinological investigation2019

Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status.

N Yalla, G Bobba, G Guo, A Stankiewicz, R Ostlund

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05346419 (Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05346419 nacompletednot on this mapstarted 2021, after this paper: background citation

Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients

TypeinterventionalSponsorHospital Regional 1o de OctubreRan2021 to 2022Enrolled33ConditionsPostmenopausal Osteoporosis, Hypovitaminosis D, HyperparathyroidismArmsRisedronate, Vitamin D
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

N YallaWashington University, St. Louis, MO, USA.
G BobbaRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
G GuoRoche Diagnostics Inc., Indianapolis, IN, USA.
A StankiewiczRoche Diagnostics Inc., Indianapolis, IN, USA.
R OstlundWashington University, St. Louis, MO, USA. rostlund@wustl.edu.
Roche (United States) · USWashington University in St. Louis · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeParathyroid hormone (PTH) concentrations are routinely measured in the diagnosis and management of bone and kidney diseases, but reference ranges can be overestimated if determined in otherwise healthy individuals for whom vitamin D deficiency was not evaluated. We establish PTH reference ranges in apparently healthy, normocalcemic, normophosphatemic individuals categorized by 25-hydroxyvitamin D (25(OH)D) status using the Elecsys

methodsThis prospective, non-interventional study measured PTH in serum from 653 apparently healthy adults [56.7% female; 68.2% white/Caucasian; 28.6% African American; median age 44 years (range 21-83)] from three diverse geographic sites across the USA during summer and winter months. Subjects were classified by concomitant vitamin D sufficiency (≥ 30 ng/mL), insufficiency (> 20 to < 30 ng/mL) or deficiency (≤ 20 ng/mL).

resultsIn vitamin D sufficiency, median PTH was 31.9 pg/mL [range (2.5th-97.5th percentile) 17.9-58.6] compared with 35.5 pg/mL (17.0-60.4) for insufficiency, and 39.8 pg/mL (19.5-86.4) for deficiency. A significant inverse relationship was found between PTH and 25(OH)D (P < 0.001). After accounting for vitamin D, potential effects of race or season as covariates were relatively small or absent.

conclusionsUpper reference limits (URL) for PTH in vitamin D sufficiency/insufficiency were similar and lower than current values. Clinically important PTH elevations were observed in vitamin D deficiency, where revised reference ranges with a higher URL may be appropriate. These data may help to distinguish vitamin D-related PTH elevations from other causes [e.g., primary (normocalcemic) or secondary hyperparathyroidism].

Indexed as

AdultAgedAged, 80 and overBiomarkersFemaleFollow-Up StudiesHumansMaleMiddle AgedParathyroid HormonePrognosisProspective StudiesReference ValuesUnited StatesVitamin DVitamin D DeficiencyBiomarkersParathyroid HormoneVitamin DVitamins25-Hydroxyvitamin D (25(OH)D)Parathyroid hormoneReference rangeVitamin D

Identifiers

PMID31273631
PMCPMC6790182
OpenAlexW2954922574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.